Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration

Biological Chemistry

Volumn 389, Issue 6, 2008, Pages 739-745

  Scarisbrick, Isobel A ^a,b   Linbo, Rachel ^b   Vandell, Alexander G ^a   Keegan, Mark ^b   Blaber, Sachiko I ^c   Blaber, Michael ^c   Sneve, Diane ^b   Lucchinetti, Claudia F ^b   Rodriguez, Moses ^b   Diamandis, Eleftherios P ^d  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic   (United States)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Axon injury; Kallikrein; Prognosis; Serine protease

Indexed keywords

KALLIKREIN; KALLIKREIN 1; KALLIKREIN 6;

ADULT; BLOOD SAMPLING; BRAIN NERVE CELL; CELL LOSS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLUOROMETRY; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; REMISSION; SEROLOGY; STATISTICAL SIGNIFICANCE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEURODEGENERATIVE DISEASES;

MURINAE;

EID: 47549115421     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.085     Document Type: Conference Paper

References (52)

1. Akenami, F.O., Koskiniemi, M., Farkkila, M., and Vaheri, A. (1997). Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease. J. Clin. Pathol. 50, 157-160.
2. Aliberti, J., Viola, J.P., Vieira-de-Abreu, A., Bozza, P.T., Sher, A., and Scharfstein, J. (2003). Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J. Immunol. 170, 5349-5353.
3. Anisowicz, A., Sotiropoulou, G., Stenman, G., Mok, S.C., and Sager, R. (1996). A novel protease homolog differentially expressed in breast and ovarian cancer. Mol. Med. 2, 624-636.
4. Araujo, R.C., Kettritz, R., Fichtner, I., Paiva, A.C., Pesquero, J.B., and Bader, M. (2001). Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. Biol. Chem. 382, 91-95.
5. Bernett, M.J., Blaber, S.I., Scarisbrick, I.A., Dhanarajan, P., Thompson, S.M., and Blaber, M. (2002). Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277, 24562-24570.
6. Bhoola, K., Ramsaroop, R., Plendl, J., Cassim, B., Dlamini, Z., and Naicker, S. (2001). Kallikrein and kinin receptor expression in inflammation and cancer. Biol. Chem. 382, 77-89.
7. Blaber, S.I., Scarisbrick, I.A., Bernett, M.J., Dhanarajan, P., Seavy, M.A., Jin, Y., Schwartz, M.A., Rodriguez, M., and Blaber, M. (2002). Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41, 1165-1173.
8. Blaber, S.I., Ciric, B., Christophi, G.P., Bernett, M.J., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Targeting kallikrein 6-proteolysis attenuates CNS inflammatory disease. FASEB J. 19, 920-922.
9. Blaber, S.I., Yoon, H., Scarisbrick, I.A., Juliano, M.A., and Blaber, M. (2007). The autolytic regulation of human kallikrein-related peptidase 6. Biochemistry 46, 5209-5217.
10. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
11. Cardin, A.D., Witt, K.R., Chao, J., Margolius, H.S., Donaldson, V.H., and Jackson, R.L. (1984). Degradation of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins. J. Biol. Chem. 259, 8522-8528.
12. Chandler, S., Cossins, J., Lury, J., and Wells, G. (1996). Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-a fusion protein. Biochem. Biophys. Res. Commun. 228, 421-429.
13. Christophi, G.P., Isackson, P.J., Blaber, S., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J. Neurochem. 91, 1439-1449.
14. Currie, M.G., Geller, D.M., Chao, J., Margolius, H.S., and Needleman, P. (1984). Kallikrein activation of a high molecular weight atrial peptide. Biochem. Biophys. Res. Commun. 120, 461-466.
15. Cuzner, M.L., Gveric, D., Strand, C., Loughlin, A.J., Paemen, L., Opdenakker, G., and Newcombe, J. (1996). The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55, 1194-1204.
16. Diamandis, E.P., Yousef, G.M., Petraki, C., and Soosaipillai, A.R. (2000). Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin. Biochem. 33, 663-667.
17. Diamandis, E.P., Scorilas, A., Fracchioli, S., Van Gramberen, M., De Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G.M., Stenman, U.H., et al. (2003). Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21, 1035-1043.
18. Gan, L., Lee, I., Smith, R., Argonza-Barrett, R., Lei, H., McCuaig, J., Moss, P., Paeper, B., and Wang, K. (2000). Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 257, 119-130.
19. Gearing, A.J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J.M., Crimmin, M., Davidson, A.H., Drummond, A.H., Galloway, W.A., Gilbert, R., et al. (1995). Matrix metalloproteinases and processing of pro-TNF-α. J. Leukoc. Biol. 57, 774-777.
20. Gijbels, K., Masure, S., Carton, H., and Opdenakker, G. (1992). Gelatinase in cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41, 29-34.
21. Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A., Ashworth, L.K., and Clements, J.A. (2000). Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. 275, 37397-37406.
22. Hellal, F., Pruneau, D., Palmier, B., Faye, P., Croci, N., Plotkine, M., and Marchand-Verrecchia, C. (2003). Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J. Neurotrauma 20, 841-851.
23. Lassmann, H. (2007). Multiple sclerosis: is there neurodegeneration independent from inflammation? J. Neurol. Sci. 259, 3-6.
24. Lesuisse, C. and Martin, L.J. (2002). Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. J. Neurobiol. 51, 9-23.
25. Lundwall, A., Band, V., Blaber, M., Clements, J.A., Courty, Y., Diamandis, E.P., Fritz, H., Lilja, H., Malm, J., Maltais, L.J., et al. (2006). A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 387, 637-641.
26. Mahabeer, R., Naidoo, S., and Raidoo, D.M. (2000). Detection of tissue kallikrein and kinin B1 and B2 receptor mRNAs in human brain by in situ RT-PCR. Metab. Brain Dis. 15, 325-335.
27. Marceau, F., Hess, J.F., and Bachvarov, D.R. (1998). The B1 receptors for kinins. Pharmacol. Rev. 50, 357-386.
28. Noda, M., Sasaki, K., Ifuku, M., and Wada, K. (2007). Multifunctional effects of bradykinin on glial cells in relation to potential anti-inflammatory effects. Neurochem. Int. 51, 185-191.
29. Noseworthy, J.H., O'Brien, P.C., Weinshenker, B.G., Weis, J.A., Petterson, T.M., Erickson, B.J., Windebank, A.J., Whisnant, J.P., Stolp-Smith, K.A., Harper, C.M. Jr, et al. (2000). IV immunoglobulin does not reverse established weakness in MS. Neurology 55, 1135-1143.
30. Ole-MoiYoi, O.K., Pinkus, G.S., Spragg, J., and Austen, K.F. (1979). Identification of human glandular kallikrein in the β cell of the pancreas. N. Engl. J. Med. 300, 1289-1294.
31. Petraki, C.D., Karavana, V.N., Skoufogiannia, P.T., Little, S.P., Howarth, D.J.C., Yousef, G.M., and Diamandis, E.P. (2001). The spectrum of human kallikrein 6 (Zyme/Protease M/Neurosin) expression in human tissues as assessed by immunohistochemistry. J. Histochem. Cytochem. 49, 1431-1441.
32. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., Phillips, J.T., Lublin, F.D., Giovannoni, G., Wajgt, A., et al. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910.
33. Raidoo, D.M., Ramsaroop, R., Naidoo, S., and Bhoola, K.D. (1996). Regional distribution of tissue kallikrein in the human brain. Immunopharmacology 32, 39-47.
34. Rosenberg, G.A., Dencoff, J.E., Correa, N. Jr, Reiners, M., and Ford, C.C. (1996). Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46, 1626-1632.
35. Scarisbrick, I.A. (2008). The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease. Curr. Top. Microbiol. Immunol. 318, 133-175.
36. Scarisbrick, I.A., Towner, M.D., and Isackson, P.J. (1997). Nervous system specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J. Neurosci. 17, 8156-8168.
37. Scarisbrick, I.A., Isackson, P.J., Ciric, B., Windebank, A.J., and Rodriguez, M. (2001). MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J. Comp. Neurol. 431, 347-361.
38. Scarisbrick, I.A., Blaber, S.I., Lucchinetti, C.F., Genain, C.P., Blaber, M., and Rodriguez, M. (2002). Activity of a newly identified serine protease in CNS demyelination. Brain 125, 1283-1296.
39. Scarisbrick, I.A., Blaber, S.I., Tingling, J.T., Rodriguez, M., Blaber, M., and Christophi, G.P. (2006). Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J. Neuroimmunol. 178, 167-176.
40. Sealey, J.E., Atlas, S.A., Laragh, J.H., Oza, N.B., and Ryan, J.W. (1978). Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin. Nature 275, 144-145.
41. Shaw, J.L. and Diamandis, E.P. (2007). Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 53, 1423-1432.
42. Terayama, R., Bando, Y., Yamada, M., and Yoshida, S. (2005). Involvement of neuropsin in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 52, 108-118.
43. Trojano, M., Avolio, C., Liuzzi, G.M., Ruggieri, M., Defazio, G., Liguori, M., Santacroce, M.P., Paolicelli, D., Giuliani, F., Riccio, P., and Livrea, P. (1999). Changes of serum ICAM-1 and MMP-9 induced by IFNβ-1b treatment in relapsing-remitting MS. Neurology 53, 1402-1408.
44. Uchida, A., Oka, Y., Aoyama, M., Suzukim, S., Yokoi, T., Katano, H., Mase, M., Tada, T., Asai, K., and Yamada, K. (2004). Expression of myelencephalon-specific protease in transient middle cerebral artery occlusion model of rat brain. Mol. Brain Res. 126, 129-136.
45. Waubant, E., Goodkin, D.E., Gee, L., Bacchetti, P., Sloan, R., Stewart, T., Andersson, P.-B., Stabler, G., and Miller, K. (1999). Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Am. Acad. Neurol. 53, 1397-1401.
46. Waubant, E., Goodkin, D., Bostrom, A., Bacchetti, P., Hietpas, J., Lindberg, R., and Leppert, D. (2003). IFNb lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60, 52-57.
47. Wong, G.W., Yang, Y., Yasuda, S., Li, L., and Stevens, R.L. (2003). Mouse mast cells express the tryptic protease neuropsin/Prss19. Biochem. Biophys. Res. Commun. 303, 320-325.
48. Xia, C.F., Yin, H., Yao, Y.Y., Borlongan, C.V., Chao, L., and Chao, J. (2006). Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene Ther. 17, 206-219.
49. Yamashiro, K., Tsuruoka, N., Kodama, S., Tsujimoto, M., Yamamura, Y., Tanaka, T., Nakazato, H., and Yamaguchi, N. (1997). Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim. Biophys. Acta 1350, 11-14.
50. Yoon, H., Laxmikanthan, G., Lee, J., Blaber, S.I., Rodriguez, A., Kogot, J.M., Scarisbrick, I.A., and Blaber, M. (2007). Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J. Biol. Chem. 282, 31852-31864.
51. Yousef, G.M., Chang, A., Scorilas, A., and Diamandis, E.P. (2000). Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys. Res. Commun. 276, 125-133.
52. Zarghooni, M., Soosaipillai, A., Grass, L., Scorilas, A., Mirazimi, N., and Diamandis, E.P. (2002). Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin. Biochem. 35, 225-231.